Major amendments containing new clinical trial data or analyses are driving the high usage of three-month extensions to PDUFA goal dates over the past year, an analysis of the Pink Sheet’s US FDA Performance Tracker shows.
Furthermore, those major amendments are followed, overwhelmingly, by FDA approval.